Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem

Novel EGFR inhibitor shows potential in REZILIENT 3
In the phase III REZILIENT* 3 trial, adding zipalertinib to chemotherapy improves progression-free survival (PFS) in patients with treatment-naïve metastatic non-small cell lung cancer (NSCLC) harbouring EGFR exon 20 insertion mutations (ex20ins-mut).

Dolutegravir knocks down HIV faster than bictegravir in French study
Final analysis of the BicDol study, presented at AIDS 2026, suggests that a first-line triple antiretroviral regimen containing dolutegravir suppresses HIV more rapidly than one containing bictegravir, particularly among patients with the highest viral loads.

Antibiotic use ups risk of IBD flare-ups
Use of antibiotics for nongastrointestinal (non-GI) infections results in a three- to fivefold increase in the risk of inflammatory bowel disease (IBD) flare-ups, a study has found. The risk gradually declines and returns to baseline level about 6 weeks after exposure.






